Application No.: 10/740,208 Docket No.: G-33056A LNG File No. 63501.US

## AMENDMENTS TO THE CLAIMS

- (CURRENTLY AMENDED) A modified release pharmaceutical composition in the form of a capsule, the capsule comprising:
  - -a coated or uncoated capsule body
- -a coated or uncoated capsule cap, wherein when the capsule cap is coated, the coating thickness of the capsule body and the cap are different
  - -at least one tablet
  - -a granulate.
- (ORIGINAL) The pharmaceutical composition according to claim 1 where the granulate comprises an active substance.
- (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the tablet and the granulate comprise an active substance.
- 4. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 3 wherein the active substance is selected from the active substances having an absorption window in the upper part of the gastrointestinal tract.
- 5. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 4 wherein the active substance is selected from the active substances from the groups: antihypertensives, peptidomimetic substances, antiulcer agents, analgesics, antipsychotics, antidepressants, antiepileptics, cytostatics, antimigraine agents, antiviral substances, antibiotics, anti-inflammatory agents, sedatives, antidiabetic agents, antihistamines, vitamins, bronchodilators, diuretics, hypolipemic agents, antiobesity agents.
- (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the capsule body and the cap are made from hydroxypropyl methylcellulose.

Ket No.: G-33056A I NG File No. 63501.US

7. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated with a coating which is insoluble in an acidic medium.

- 8. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated with a coating which is insoluble in an acidic medium.
- (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated with a coating which is insoluble independent of pH.
- 10. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated with a coating which is insoluble independent of pH.
- 11. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated with a coating which is poorly soluble in an acidic medium.
- 12. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated with a coating which is poorly soluble in an acidic medium.
- 13. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated with a coating which is poorly soluble independent of pH.
- 14. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated with a coating which is poorly soluble independent of pH.
- 15. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated with a coating which is a combination of insoluble and soluble polymers.

LNG File No. 63501.US

16. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated with a coating which is a combination of insoluble and soluble polymers.

17. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the

capsule cap is coated with a coating which is better soluble than a coating of the

capsule body.

18. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the

capsule body is coated with a coating which is better soluble than a coating of the

capsule cap.

19. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the

capsule body and cap are coated with the same coating.

20. (CANCELED)

21. (CANCELED)

22. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the

capsule body coating comprises copolymers of acrylic and methacrylic acid.

23. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the

capsule cap comprises copolymers of acrylic and methacrylic acid.

24. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the

capsule body coating comprises a combination of ethylcellulose and

hydroxypropylmethylcellulose.

4

LNG File No. 63501.US

25. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap coating comprises a combination of ethylcellulose and hydroxypropylmethylcellulose.

- 26. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body coating comprises a combination of ethylcellulose and hydroxypropylcellulose.
- 27. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap coating comprises a combination of ethylcellulose and hydroxypropylcellulose.
- 28. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule body is coated and the capsule cap uncoated.
- 29. (WITHDRAWN) The pharmaceutical composition according to claim 1 wherein the capsule cap is coated and the capsule body uncoated.
- 30. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the granulate comprises at least one lipophilic or hydrophilic substance.
- 31. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 1 wherein the granulate comprises hydroxypropylmethylcellulose.
- 32. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the granulate optionally comprises fillers, binders, disintegrants, glidants, lubricants and excipients that enhance the absorption of drugs from gastrointestinal tract.
- 33. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the composition of the tablet is the same as the composition of the granulate.

LNG File No. 63501.US

34. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the composition of the tablet is different from the composition of granulate.

- 35. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the tablet comprises at least one lipophilic or hydrophilic substance.
- 36. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 1 wherein the tablet comprises hydroxypropylmethylcellulose.
- 37. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the tablet optionally comprises fillers, binders, disintegrants, glidants, lubricants and excipients that enhance the absorption of drugs from gastrointestinal tract.
- 38. (ORIGINAL) The pharmaceutical composition according to claim 1 wherein the tablet does not contain an active substance.
- 39. (ORIGINAL) The pharmaceutical composition according to claim 1 which comprises one, two or more tablets.
- 40. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 39 wherein the composition of all tablets is the same.
- 41. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 39 wherein the composition of the tablets is different.
- 42. (PREVIOUSLY AMENDED) The pharmaceutical composition according to claim 39 wherein the tablets contain different active substances.